OPKO HEALTH, INC.
OPKNasdaq
$1.19
0.0%Jul 17 close · end-of-day
Price
1Y↓ -12.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$903.1M
Enterprise Value
$574.7M
P/E
—
P/S
1.6
P/B
0.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$581.1M
Net Income (TTM)
-$212.9M
Free Cash Flow (TTM)
—
Gross Margin
36.0%
Operating Margin
-17.4%
Net Margin
-36.6%
ROE
-17.7%
ROIC
-9.1%
Debt / Equity
0.0
Net Cash
$328.3M
Return 1Y
-13.8%
Company profile
OPKO Health, Inc. engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency.
- CEO
- Phillip Frost
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4,200
- Headquarters
- Florida
- Website
- opko.com
Earnings
OPK Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$124.2M↓ -17.2%
Diluted EPS-$0.07↓ -30.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $1.4B | $1.8B | $1.0B | $863.5M | $713.1M | $606.9M |
| Gross profit | — | — | $288.2M | $318.1M | $218.5M | $205.9M |
| Operating income | $57.7M | $18.8M | -$226.3M | -$157.0M | -$152.1M | -$117.4M |
| Net income | $30.6M | -$30.1B | -$328.4B | -$188.9B | -$53.2B | -$225.7B |
| Diluted EPS | $0.05 | -$0.05 | -$0.46 | -$0.25 | -$0.08 | -$0.30 |
| Operating cash flow | $39.5M | $38.3M | -$95.2M | -$28.2M | -$183.5M | -$178.5M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | 28.7% | 36.8% | 30.6% | 33.9% |
| Operating margin | 4.0% | 1.1% | -22.5% | -18.2% | -21.3% | -19.3% |
| Net margin | 2.1% | -1698.5% | -32703.3% | -21871.9% | -7463.3% | -37187.0% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $182.2M | $173.6M | $183.6M | $150.0M | $156.8M | $151.7M | $148.5M | $124.2M |
| Gross profit | $51.7M | $40.1M | $84.7M | $42.6M | $49.4M | $49.9M | $64.0M | $45.8M |
| Operating income | -$61.7M | -$67.2M | $48.2M | -$67.2M | -$60.0M | $48.1M | -$38.3M | -$51.0M |
| Net income | -$10.3M | $24.9M | $14.0M | -$67.6M | -$148.4M | $21.6M | -$31.3M | -$54.8M |
| Diluted EPS | -$0.01 | $0.03 | $0.01 | -$0.10 | -$0.19 | $0.03 | -$0.04 | -$0.07 |
| Operating cash flow | -$26.4M | -$77.1M | -$44.4M | -$34.6M | -$83.4M | -$34.6M | -$25.9M | -$19.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | 28.4% | 23.1% | 46.1% | 28.4% | 31.5% | 32.9% | 43.1% | 36.8% |
| Operating margin | -33.9% | -38.7% | 26.3% | -44.8% | -38.3% | 31.7% | -25.8% | -41.1% |
| Net margin | -5.7% | 14.3% | 7.6% | -45.1% | -94.7% | 14.3% | -21.1% | -44.2% |
Company news
Jun 15, 2026
Jun 7, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-03-20 | PAGANELLI JOHN A | Buy | 10,000 | $1.14 | $11,350.00 | filing |
| 2025-11-21 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 192,870 | $1.34 | $257,481.45 | filing |
| 2025-11-21 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 191,490 | $1.33 | $254,681.70 | filing |
| 2025-11-21 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 102,371 | $1.30 | $133,082.30 | filing |
| 2025-11-21 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 89,375 | $1.33 | $118,421.88 | filing |
| 2025-11-21 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 3,894 | $1.32 | $5,140.08 | filing |
| 2025-11-20 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 211,948 | $1.33 | $281,890.84 | filing |
| 2025-11-20 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 161,818 | $1.34 | $216,027.03 | filing |
| 2025-11-20 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 119,129 | $1.32 | $157,250.28 | filing |
| 2025-11-20 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 47,105 | $1.33 | $62,414.13 | filing |
| 2025-11-20 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 24,579 | $1.34 | $32,935.86 | filing |
| 2025-11-20 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 13,664 | $1.35 | $18,446.40 | filing |
| 2025-11-20 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 1,757 | $1.35 | $2,363.17 | filing |
| 2025-11-19 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 198,904 | $1.32 | $261,558.76 | filing |
| 2025-11-19 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 155,496 | $1.32 | $205,254.72 | filing |
| 2025-11-19 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 66,504 | $1.31 | $87,120.24 | filing |
| 2025-11-19 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 58,160 | $1.29 | $74,735.60 | filing |
| 2025-11-19 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 36,325 | $1.28 | $46,496.00 | filing |
| 2025-11-19 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 30,082 | $1.30 | $39,106.60 | filing |
| 2025-11-19 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 21,236 | $1.30 | $27,500.62 | filing |
| 2025-11-19 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 12,993 | $1.31 | $16,955.87 | filing |
| 2025-11-19 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 300 | $1.29 | $387.00 | filing |
| 2025-11-18 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 212,608 | $1.28 | $271,075.20 | filing |
| 2025-11-18 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 83,556 | $1.29 | $107,369.46 | filing |
| 2025-11-18 | FROST PHILLIP MD ET AL· CEO & Chairman | Buy | 69,728 | $1.28 | $89,251.84 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.